Evidence map›Paper›PMID 25548477›Full record

ReviewWorld journal of gastroenterology2014

Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Iyad Issa, Rami Moucari

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Effects ofNutrients · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Probiotics in Children: What Is the Evidence?Pediatric gastroenterology, hepatology & nutrition · 2017
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iyad IssaIyad Issa, Department of Gastroenterology and Hepatology, Rafik Hariri University Hospital, Hamra, Beirut 2034-7304.
Rami MoucariIyad Issa, Department of Gastroenterology and Hepatology, Rafik Hariri University Hospital, Hamra, Beirut 2034-7304.
Rafik Hariri University Hospital · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics use has increased tremendously over the past ten years. This was coupled with a surge of data relating their importance in clinical practice. Antibiotic-associated diarrhea, whose frequency has risen recently, was one of the earliest targets with data published more than ten years ago. Unfortunately, available trials suffer from severe discrepancies associated with variability and heterogeneity of several factors. Most published randomized controlled trials and subsequent meta-analyses suggest benefit for probiotics in the prevention of antibiotic-associated diarrhea. The same seems to also apply when the data is examined for Clostridium difficile-associated colitis. However, the largest randomized double-blind placebo-controlled trial to date examining the use of a certain preparation of probiotics in antibiotic-associated diarrhea showed disappointing results, but it was flawed with several drawbacks. The commonest species of probiotics studied across most trials is Lactobacillus; however, other types have also shown similar benefit. Probiotics have enjoyed an impeccable safety reputation. Despite a few reports of severe infections sometimes leading to septicemia, most of the available trials confirm their harmless behavior and show similar adverse events compared to placebo. Since a consensus dictating its use is still lacking, it would be advisable at this point to suggest prophylactic use of probiotics to certain patients at risk for antibiotic-associated diarrhea or to those who suffered previous episodes.

Indexed as

Anti-Bacterial AgentsClostridioides difficileDiarrheaEnterocolitis, PseudomembranousHumansIntestinesProbioticsRisk AssessmentRisk FactorsTreatment OutcomeAnti-Bacterial AgentsAntibiotic-associated diarrheaBifidobacteriumClostridium difficileLactobacillusPreventionProbiotics

Identifiers

PMID25548477
PMCPMC4273129
OpenAlexW613004803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.